
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
Certain mutations in the androgen receptor protein appear to cause advanced and invasive prostate cancer, at least in a mouse model, according to a recent study in the Proceedings of the National Academy of Sciences (2005; 102:1151-6).





